Innodem, Novartis Team Up on Trial Testing Eye-tracking Technology

Innodem, Novartis Team Up on Trial Testing Eye-tracking Technology

308795

Innodem, Novartis Team Up on Trial Testing Eye-tracking Technology

Innodem Neurosciences is teaming up with Novartis Canada on a breakthrough clinical trial to evaluate if Innodem’s digital biomarker eye-tracking technology can monitor disease progression in people with multiple sclerosis (MS). The trial will test Innodem’s “easy-to-use, affordable technology,” which works using visible light, with no special infrared cameras required. “This partnership is the result of an ongoing collaboration that was architected over the past two years,” Marc Reeves, co-founder and chief business officer of Innodem,…

You must be logged in to read/download the full post.